Aberdeen Group plc Has $48.85 Million Stock Holdings in Cencora, Inc. $COR

Aberdeen Group plc grew its position in Cencora, Inc. (NYSE:COR) by 5.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 158,564 shares of the company’s stock after purchasing an additional 8,076 shares during the quarter. Aberdeen Group plc owned approximately 0.08% of Cencora worth $48,849,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Harbour Investments Inc. raised its holdings in Cencora by 108.2% in the 2nd quarter. Harbour Investments Inc. now owns 1,951 shares of the company’s stock worth $585,000 after acquiring an additional 1,014 shares during the period. Private Trust Co. NA grew its position in shares of Cencora by 3.3% in the second quarter. Private Trust Co. NA now owns 1,996 shares of the company’s stock valued at $599,000 after purchasing an additional 63 shares during the last quarter. Stratos Wealth Partners LTD. increased its stake in shares of Cencora by 31.6% in the second quarter. Stratos Wealth Partners LTD. now owns 1,028 shares of the company’s stock worth $308,000 after purchasing an additional 247 shares during the period. William Blair Investment Management LLC lifted its position in shares of Cencora by 4,778.9% during the 2nd quarter. William Blair Investment Management LLC now owns 37,665 shares of the company’s stock worth $11,294,000 after purchasing an additional 36,893 shares during the last quarter. Finally, United Bank lifted its position in shares of Cencora by 4.5% during the 2nd quarter. United Bank now owns 7,032 shares of the company’s stock worth $2,109,000 after purchasing an additional 305 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on COR shares. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Mizuho increased their price objective on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Evercore lowered their price objective on shares of Cencora from $440.00 to $420.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. JPMorgan Chase & Co. upped their target price on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Finally, TD Cowen increased their price target on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $399.00.

Cencora Trading Up 2.7%

Shares of COR stock opened at $360.59 on Monday. The firm has a fifty day moving average of $347.51 and a 200-day moving average of $328.88. The stock has a market cap of $70.15 billion, a price-to-earnings ratio of 43.34, a P/E/G ratio of 1.66 and a beta of 0.68. Cencora, Inc. has a 52-week low of $237.71 and a 52-week high of $377.54. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. During the same period in the previous year, the business earned $3.73 EPS. The firm’s revenue was up 5.5% on a year-over-year basis. On average, equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. Cencora’s dividend payout ratio is currently 28.85%.

Insider Transactions at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the sale, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total value of $1,868,397.44. Following the transaction, the chief executive officer directly owned 65,746 shares of the company’s stock, valued at approximately $24,105,113.44. The trade was a 7.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 20,316 shares of company stock valued at $7,151,265. Corporate insiders own 0.38% of the company’s stock.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.